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Introduction: Quinoline-3-carboximide compounds, such as paquinimod, which targets the
protein S100A9, have demonstrated efﬁcacy in treating autoimmune diseases. S100A9, in
association with S100A8, forms the heterodimer S100A8/S100A9, known as calprotectin;
that  has been shown to be upregulated in numerous inﬂammatory disorders. We  had previ-
ously demonstrated protection from glomerular disease in S100A9-deﬁcient mice. The aim
of  this study was to assess the efﬁcacy of paquinimod in the prevention and treatment of
experimental glomerulonephritis.
Methods: Nephrotoxic nephritis (NTN) was induced in C57BL/6 mice according to our
standard protocol. Mice were treated with different doses of paquinimod either at disease
induction (prevention group) or two days following induction (therapeutic group) and sacri-
ﬁced  8 days following induction. Disease was assessed histologically (number of glomerular
crescents, degree of glomerular thrombosis, number of inﬁltrating leucocytes and calpro-
tectin expression) and biochemically (serum creatinine and urea levels, and urinary levelsof  protein).
Results: Neither treatment with low (0.5 mg/kg) or high (25 mg/kg) doses of paquinimod,given preventatively or therapeutically, led to disease attenuation, as assessed by bio-
chemical or histological parameters. Additionally, we found trends for an increase in renal
Abbreviations: TLR-4, toll-like receptor 4; ANCA, Anti-neutrophil cytoplasm antibody associated vasculitis; AAV, Anti-neutrophil cyto-
lasm antibody associated vasculitis; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; MS, multiple sclerosis; RAGE,
dvanced glycosylation end product-speciﬁc receptor; IL8, interleukin-8; ICAM-1, intercellular adhesion molecule 1; WT, wild-type;
100A9−/−, mice deﬁcient in S100A9; TLR4−/−, mice deﬁcient in TLR4 receptor; NTS, sheep anti-mouse nephrotoxic serum; CFA, complete
reund’s adjunvant; LPS, lipopolysaccharide; PaqP, Prevention group; PaqT, Therapeutic group; PAS, periodic acid-Schiff; CPR, C-reactive
rotein.
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glomerular calprotectin expression in the high dose groups, suggesting a possible feedback
regulation of calprotectin expression.
Conclusions: Our results show that paquinimod does not successfully prevent or treat mice
with  NTN. Other models of immune-mediated glomerulonephritis need to be tested to
investigate the therapeutic potential of this compound in renal disease.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
El  tratamiento  con  3-carboxamina-quinolina  no  previene  con  éxito  una
glomerulonefritis  immuno-mediada  en  un  modelo  experimental  en
ratones
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Introducción: Los compuestos relacionados con la 3-carboxamina-quinolina han demostrado
eﬁcacia en el tratamiento de enfermedades autoinmunes. Uno de estos compuestos, el
paquinimod, ejerce su función a través del targeting de la proteína S100A9. La proteína
S100A9, en asociación con S100A8, forma el heterodímero S100A8/S100A9, conocido como
calprotectina, que se ha demostrado que está elevada en variadas enfermedades inﬂamato-
rias.  Habíamos demostrado anteriormente la protección contra la enfermedad glomerular
en  ratones deﬁcientes de S100A9. El objetivo de este estudio fue evaluar la eﬁcacia de
paquinimod en la prevención y el tratamiento de la glomerulonefritis experimental.
Métodos: La nefritis nefrotóxica (NTN) se indujo en ratones C57BL/6 de acuerdo con el pro-
tocolo estándar. Los ratones fueron tratados con diferentes dosis de paquinimod en el
momento de la inducción de la enfermedad (grupo de prevención) o 2 días después de la
inducción (grupo terapéutico)y se sacriﬁcaron 8 días después de la inducción. La enfermedad
se  evaluó histológicamente (número de semilunas glomerulares, el grado de trombosis
glomerular, número de leucocitos inﬁltrantes y de expresión de calprotectina) y bioquímico
(niveles séricos de creatinina y urea, y los niveles urinarios de proteínas).
Resultados: Ninguno de los tratamientos con bajas (0,5 mg/kg) o altas (25 mg/kg) dosis de
paquinimod, administrados preventiva o terapéuticamente, resultaron en la atenuación de
la  enfermedad,según los parámetros bioquímicos o histológicos. Además, encontramos una
tendencia al aumento en la expresión renal de la calprotectina glomerular en los grupos con
dosis altas, lo que indica una posible regulación de la retroalimentación de la expresión de
calprotectina.
Conclusiones: Nuestros resultados muestran que el paquinimod no puede prevenir ni tratar
con  éxito la NTN en los ratones. Otros modelos de glomerulonefritis inmunomediadas
necesitan ser testados para investigar el potencial terapéutico de este compuesto en la
enfermedad renal.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Paquinimod belongs to the class of quinoline-3-carboximide
derivatives, compounds that have demonstrated efﬁcacy in
treating autoimmune diseases in both humans and mice.1–5
Linomide, the ﬁrst compound of this class, was effective
in treatment of multiple sclerosis (MS) in phase II studies;
however, cardiovascular toxicity during phase III studies led
to premature trial termination.6,7 Subsequently, two new
compounds with improved safety proﬁles and increased
potency were investigated. The ﬁrst, Laquinimod exhibited
clinical efﬁcacy as well as favourable safety in MS  patients8–10
and is still being investigated for the treatment of MS. Theby-nc-nd/4.0/).
second, Paquinimod effectively inhibited disease in experi-
mental lupus prone mice, and was well tolerated (in doses
up to 3 mg/day) in SLE patients with low disease activity,
however, at higher doses (up to 6 mg/day) systemic adverse
effects consisting of myalgias and arthralgias were reported.
In addition, transient increases in inﬂammatory cells and
acute phase reactants were seen at all doses, but most marked
at the higher dose range.11
The S100A9 protein has been identiﬁed as one target
molecule of Paquinimod, disrupting binding of this pro-
tein to one of its receptors, TLR-4 but not to the advanced
glycosylation end product-speciﬁc receptor (RAGE).12 In
association with S100A8, S100A9 forms the heterodimer
S100A8/S100A9, termed calprotectin. Calprotectin is found
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bundantly in neutrophils, monocytes and early differen-
iated macrophages and is involved in calcium-dependent
ignalling, cell differentiation, cell cycle progression and
ytoskeleton-membrane interactions.13 Upon phagocyte
ctivation with the inﬂamed endothelium, calprotectin is
ecreted, binds to endothelial cells stimulating the secretion
f pro-inﬂammatory cytokines such as interleukin-8 (IL8) and
ncreasing the expression of Intercellular adhesion molecule
(ICAM-1), involved in the further recruitment of leucocytes,
romoting the impairment of endothelial monolayer integrity
nd inducing apoptosis and necrosis.14–16
Calprotectin has been demonstrated to be upregulated in
any inﬂammatory disorders, such as SLE, RA, idiopathic
uvenile arthritis, Kawasaki’s disease and AAV.17–22 In patients
ith active SLE, serum calprotectin levels correlate with dis-
ase activity assessed by laboratory and clinical parameters.17
n patients with limited systemic AAV, failure to suppress
erum calprotectin whilst on immunosuppressive treatment
as associated with subsequent disease relapse, suggesting
hat calprotectin may be a useful biomarker to predict future
ares.22
In animal models of autoimmunity, calprotectin and its
LR4 receptor have been implicated in mediating disease.
n accelerated NTN, a model of immune mediated glomeru-
onephritis, wild-type (WT) mice with glomerulonephritis
ave increased serum levels of S100A8/A9, while mice deﬁ-
ient in S100A9 (S100A9−/−) or the TLR4 receptor (TLR4−/−) are
igniﬁcantly protected from disease.23,24 In a model of autoim-
unity in mice overexpressing CD40L, S100A8/S100A9 was
ritical for the induction of dermatitis and nephritis, as well
s the expansion of autoreactive CD8 T-cells, and the devel-
pment of autoantibodies.25 Together these data suggest that
100A8/A9 blockade could be a promising therapeutic target
n human glomerulonephritis including lupus nephritis and
NCA associated glomerulonephritis. In the present study we
ssessed the efﬁcacy of Paquinimod in the prevention and
reatment of murine NTN.
ethods
nimals,  induction  of  accelerated  nephrotoxic  nephritis
NTN)  and  treatment  with  Paquinimod
nimals
ale C57BL/6 mice were between 8 and 12 weeks of age, and
ere bred in house. All experiments were performed under the
erms of the Animals (Scientiﬁc Procedures) Act 1986, under
K Home Ofﬁce animal welfare licences
ephrotoxic  nephritis
heep anti-mouse nephrotoxic serum (NTS) was generated
ccording to previously published methods.26 Disease was
nduced by pre-immunising mice sub-cutaneously with sheep
gG (0.2 mg)  in Complete Freund’s Adjunvant (CFA, Sigma).
ive days later (day 0), mice were injected intravenously with
00 l of sheep NTS (diluted 1:3 in sterile 0.9% NaCl) and
ntraperitoneal lipopolysaccharide (LPS, 0.1 g/mouse). Mice
ere sacriﬁced 8 days later. Groups of 7–10 mice were used
er treatment cohort.(6):687–693 689
Treatment  with  different  doses  of  Paquinimod
Mice were treated with Paquinimod (from Active Biotech AB,
Lund, Sweden) dissolved in drinking water available ad libi-
tum, after assessment of the average daily ﬂuid intake of
the mice. In the ﬁrst experiment, the compound was used at
dosage of 0.5 mg/kg per day starting at day 0 in the treatment
group (10 mice: paquinimod), while control mice drank normal
water (10 mice: controls). In the second experiment, a dosage
of 25 mg/kg per day was used, starting at day 0 (prevention
group: PaqP, 7 mice), or day 2 (therapeutic group: PaqT, 7 mice)
or untreated (Control, 7 mice). Mice were placed in metabolic
cages overnight, the day before sacriﬁce and urine collected.
Assessment  of  renal  injury
Serum creatinine, urea, ALT and albumin were measured in
the clinical pathology laboratory, Mary Lyon Centre, Medical
research Council, Harwell. In all experiments, urine was col-
lected after housing mice in metabolic cages overnight with
free access to food and water. Urinary protein was measured
by the sulfosalicylic acid method.27
Histology  and  immunohistochemistry
Kidneys were removed, ﬁxed in formalin and embedded
in parafﬁn for periodic acid-Schiff (PAS) and immunohis-
tochemical staining. Immunoperoxidase staining for mouse
calprotectin and macrophages was performed using a rat
anti-mouse calprotectin monoclonal antibody (clone 2B10 at
1.2 mg/ml, a gift from Prof Nancy Hogg) and a rat anti-mouse
MAC2 (at 1 mg/ml), respectively. Renal sections were analysed
for the percentages of glomerular crescents (0–100%) and the
degree of glomerular thrombosis using a standard scoring sys-
tem (0 = no PAS material, 1 = 0–25% of glomerulus affected,
2 = 25–50%, 3 = 50–75% and 4 = 75–100%).
Statistical  analysis
Statistical analysis was performed using GraphPad prism 6.0
(GraphPad Software, San Diego, CA, USA). A Mann–Whitney
test was used when comparing 2 groups. When comparing 3
groups, a one-way ANOVA test was used. Results were consid-
ered signiﬁcant when p < 0.05.
Results
Low  dose  preventative  Paquinimod  treatment
In the ﬁrst experiment, a dose of paquinimod of 0.5 mg/kg
per day was administered from day 0, based on the previ-
ously published data demonstrating efﬁcacy in a lupus mouse
model.11 All mice tolerated this dose, with no fatalities. Renal
function, assessed by serum urea and creatinine, as well
as urinary protein excretion, were not signiﬁcantly differ-
ent between Paquinmod-treated (n = 10) and control (n = 10)
mice (median serum urea Paquinimod 14.8 mmol/l (range
6.9–98.0) vs control 8.2 mmol/l (range 5.8–120); median serum
creatinine Paquinimod treated 36.6 mol/l (range 25.6–76.3)
vs control 34.3 mol/l (range 29.1–86.6); median proteinuria
690  n e f r o l o g i a 2 0 1 6;3  6(6):687–693
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Fig. 1 – Renal function assessed by (a) serum creatinine and (b) urea and (c) urinary protein excretion in control and
Paquinimod-treated animals; Renal histology assessed by (d) percentage glomerular crescents and (e) glomerular
thrombosis score in control and Paquinimod-treated animals. Medians shown. Paquinimod was administered at a dosage
of 0.5 mg/kg per day.
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Fig. 2 – Renal function assessed by (a) serum creatinine and (b) urea and (c) urinary protein excretion in controls and
animals treated with Paquinimod prophylactically (Paq-P)or therapeutically (Paq-T); Renal histology assessed by (d)
percentage glomerular crescents and (e) glomerular thrombosis score in control and Paquinimod-treated animals. Medians
shown. Paquinimod was administered at a dosage of 25 mg/kg per day.
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Fig. 3 – Immunohistochemistry for (a) calprotectin expressing cells and (c) macrophages. (b) Quantiﬁcation of mean
calprotectin positive cells per glomerulus and (d) mean glomerular macrophage number in Control, and Paquinimod treated
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tnimals (prevention group (Paq P) and therapeutic group (Pa
n Paquinimod-treated animals 9.3 mg/ml  (range 6.3–14.5) vs
ontrols 6.8 mg/ml  (range 1.1–9.1) (all p = NS)) (Fig. 1a–c).
Similarly, renal histology, revealed no signiﬁcant differ-
nces between the two groups with regards percentages of
lomerular crescents (median % crescents paquinimod 8%
range 0–60%) vs controls 10% (range 0–44) or thrombosis
cores (median thrombosis score Paquinimod 0.53 (range
–3.5) vs controls 0.1 (range 0–2.84) (Fig. 1d and e).
igh-dose  prevention  and  treatment  Paquinimod  therapy
n the second series of experiments, the dose of Paquinimod
as increased to 25 mg/kg per day, based on further pub-
ished data showing efﬁcacy in the treatment of experimental
utoimmune encephalomyelitis.5 After 8 days, 4 mice had
ied; 2 from the control group, 1 from the prevention group
nd 1 from the treatment group.
Renal function and proteinuria (Fig. 2a–c) were similar
etween the three groups(median serum creatinine con-
rol 12.1 mol/l (range 10.4–13.7) vs Paq P 17.3 mol/l (range
0.8–55.7) vs Paq T 16.7 mol/l (range 15.2–18.10); median
erum urea control 9.5 mmol/l (range 9.0–14.1) vs Paq P
5.1 mmol/l (range 10.9–148.8) vs Paq T 42.7 mmol/l (range
.1–77.3); Renal histological damage was also similar in all
hree groups with regards percentages of glomerular crescents Paquinimod administered at a dosage of 25 mg/kg per day.
(median % crescents control 0% (range 0–20) vs Paq P 4% (range
0–75) vs Paq T 0% (range 0–50) and glomerular thrombosis
scores median thrombosis score control 0.1 (range 0–0.49) vs
Paq P 0.39 (range 0–0.97) vs Paq T 0.02 (range 0–0.22) (Fig. 2d
and e).
As the drug has direct binding effect in the S100A9 and
calprotectin is abundantly expressed in early inﬂammatory
macrophages, we performed an immunoperoxidase staining
for calprotectin and macrophages (Fig. 3a and b) and quan-
tiﬁcation of these showed a trend for increased glomerular
calprotectin expression, and a similar trend in glomerular
macrophage numbers, (mean glomerular calprotectin cell
expression control 0.22 cells/glomerulus (SEM 0.1) vs Paq P 1.25
(SEM 0.6) vs Paq T 0.45 (SEM 0.2); mean glomerular macrophage
number control 2.2 cells/glomerulus (SEM 0.1) vs Paq P 3.6 (SEM
1.0) vs Paq T 4.1 (SEM 0.7)).
Discussion
Previous studies in lupus prone mice,11 experimental
autoimmune encephalomyelitis5 and collagenase induced
osteoarthritis28 have demonstrated a signiﬁcant reduction
in glomerular, central nervous system and joint inﬂam-
mation respectively following the use of prophylactic low
 0 1 6;
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and high doses of Paquinimod, a compound that inhibits
S100A9 but not S100A8, binding to TLR4. We have previously
shown that serum S100A8/A9 levels are elevated during NTN
and that S100A9 deﬁciency signiﬁcantly attenuates disease,
in part by inhibiting release of proinﬂammatory cytokines
and chemokines.25 We found no effect of S100A9 deﬁciency
on glomerular neutrophil recruitment, but noted a signiﬁ-
cant reduction in glomerular macrophage inﬁltration. In this
report, we  show that using the same NTN model, different
doses of Paquinimod administered at the time of, or following,
disease induction were not efﬁcacious in attenuating disease.
We  found a non-signiﬁcant trend of increased glomerular cal-
protectin expression in those animals given the highest dose
of Paquinimod, and a similar trend in the number of glomeru-
lar macrophages.
Denoric et al.,29 demonstrated that Paquinimod reduced
the accumulation of Ly6Chi inﬂammatory monocytes and
eosinophils, but not neutrophils in the omentum or at sub-
cutaneous sites of inﬂammation. While, in alum-induced
inﬂammation, in which neutrophils were the predominant
cell population, Paquinimod failed to reduce the accumula-
tion of inﬂammatory cells. Therefore our NTN model, which
relies on early transient neutrophil recruitment followed by
monocyte/macrophage inﬁltration into the kidney by day 3,
may not be easily attenuated by Paquinimod. Another possi-
ble explanation for our observations may relate to the ﬁndings
of Vandal et al.,30 who investigated the role of S100A8 and
S100A9 on neutrophil migration into a murine air pouch in
response to LPS. They found that LPS led to S100A8, S100A9
and S100A8/A9 in the pouch exudates that preceded the neu-
trophil accumulation. Blocking S100A8 inhibited neutrophil
migration 3 h after LPS injection, but blocking S100A9 had
no signiﬁcant effect. It is therefore possible that LPS used
in induction of our NTN model resulted in an increase of
S100A8 expressing inﬂammatory cells early on in the course of
disease.
In addition, Paquinimod appears to induce a transient
increase in levels of inﬂammatory markers, such as C-reactive
protein (CRP) and erythrocyte sedimentation rate, reported
in Paquinimod-treated SLE patients.11 These changes were
more  evident with higher dosages of Paquinimod (4.5 mg/day
and 6.0 mg/day compared to 3.0 mg/day). Similar increases in
inﬂammatory markers, were also reported in the ﬁrst weeks of
treatment from clinical trials with Laquinimod.8,9 The mecha-
nisms that cause these changes remain unclear and are being
investigated, but if replicated in our NTN model could explain
the lack of efﬁcacy observed in a short term animal model. It
is noteworthy that the efﬁcacy of Paquinimod in other exper-
imental models have utilised more  prolonged time courses
compared to ours. Our NTN model may evolve too rapidly
to dissect out any transient increase and subsequent reduc-
tion in inﬂammation that may occur with this compound, in
contrast to genetic deﬁciency of S100A9.
ConclusionsIn conclusion, we  could not show a beneﬁt from Paquini-
mod  in prevention or treatment of a murine NTN model,
despite having previously shown a beneﬁt from complete3  6(6):687–693
S100A9 deﬁciency using the same model. However, due to
the transient proinﬂammatory action of this compound, a
murine glomerulonephritis model of longer duration may
be necessary to fully test the efﬁcacy of this drug, or the
drug may need to be used in combination therapy with other
anti-inﬂammatories such as corticosteroids which could
suppress the early inﬂammatory response.
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